Article Information
History
- July 25, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Flávio Adsuara Cadegiani, MD, PhD1,2,*,
- Andy Goren, MD1,
- Carlos Gustavo Wambier, MD, PhD3 and
- Ricardo Ariel Zimerman, MD4
- 1Applied Biology, Inc. Irvine, CA, USA
- 2Corpometria Institute, Brasilia, Brazil
- 3Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, USA
- 4Hospital da Brigada Militar, Porto Alegre, Brazil
- ↵*Corresponding author:
Flavio Adsuara Cadegiani, MD, PhD Applied Biology, Inc., 17780 Fitch, Irvine, CA 92614, Flavio.cadegiani{at}unifesp.br
Posted July 25, 2021.
Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
